Procurement of a license for 12 months of access to national library of medicine - UK cprd datasets
Ended Awarded
- Contract number
- 75N91020F00001
- Awardee
-
Department Of Health UEI CGFMM2DJPAJ3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $160,000
Award facts
- Contract value 100% obligated
- $160,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541713 Research and Development in Nanotechnology
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute (NCI) awarded a $160,000 firm fixed price contract to the Department of Health, doing business as the Medicines & Healthcare Products Regulatory Agency (MHRA), for a 12-month license providing access to the National Library of Medicine's UK Clinical Practice Research Datalink (CPRD) datasets. This contract award, issued on September 24, 2020, with an ultimate completion date of September 23, 2021, represents a call against an NCI Blanket Purchase Agreement (BPA) and carries no set-aside designation. The place of performance is identified as Potomac, Maryland. The MHRA, the health department of the United Kingdom government, specializes in delivering real-world research services that support public health and clinical studies through de-identified patient data and data linkages.
Under this contract, the NCI gains access to CPRD's extensive clinical datasets and the MHRA's expertise in data integration and analytics to support epidemiological cancer research initiatives. The CPRD database provides de-identified patient data with linkages to the National Cancer Data Registry, enabling the NCI's research into factors such as hormone therapy risks and reproductive factors related to cancer outcomes. This BPA vehicle, which expires in September 2023, provides an indefinite delivery mechanism through which the NCI can procure additional licenses and services from the MHRA, leveraging the United Kingdom's established clinical datasets to advance the agency's cancer research mission.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to Department Of Health by National Cancer Institute (National Institutes of Health) on September 24, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $160,000 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a BPA call under 75N91020A00003, a blanket purchase agreement.
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award